PT Kalbe Farma Tbk. dan Entitas Anaknya/and its Subsidiaries · 2020. 10. 30. · PT Kalbe Farma...

PT Kalbe Farma Tbk. dan Entitas Anaknya/and its Subsidiaries

Laporan keuangan konsolidasian

tanggal 30 September 2020 dan

untuk periode yang berakhir pada tanggal tersebut (Belum Diaudit)/

Consolidated financial statements as of September 30, 2020 and for the period then ended (Unaudited)

The original consolidated financial statements included herein are in

the Indonesian language.

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA

LAPORAN KEUANGAN KONSOLIDASIAN TANGGAL 30 SEPTEMBER 2020 DAN

UNTUK PERIODE YANG BERAKHIR PADA TANGGAL TERSEBUT (BELUM DIAUDIT)

PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2020 AND FOR THE PERIOD THEN ENDED (UNAUDITED)

Daftar Isi Table of Contents Halaman/ Page Laporan Posisi Keuangan Konsolidasian ......................... 1-3 ............ Consolidated Statement of Financial Position Laporan Laba Rugi dan Penghasilan Consolidated Statement of Profit or Loss Komprehensif Lain Konsolidasian ............................. 4-5 ..................... and Other Comprehensive Income Laporan Perubahan Ekuitas Konsolidasian ..................... 6 ........... Consolidated Statement of Changes in Equity Laporan Arus Kas Konsolidasian ..................................... 7-8 ..................... Consolidated Statement of Cash Flows Catatan Atas Laporan Keuangan Konsolidasian .............. 9-148 ....... Notes to the Consolidated Financial Statements

***************************

The original consolidated financial statements included herein are in the Indonesian language.

Catatan atas laporan keuangan konsolidasian terlampir merupakan bagian integral dari laporan keuangan

konsolidasian.

The accompanying notes to the consolidated financial statement form an integral part of these consolidated financial

statements.

1

g

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA LAPORAN POSISI KEUANGAN KONSOLIDASIAN

Tanggal 30 September 2020 (Belum Diaudit) (Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENT

OF FINANCIAL POSITION As of September 30, 2020 (Unaudited)

(Expressed in Rupiah, unless otherwise stated) 30 September 2020/ Catatan/ 31 Desember 2019/ September 30, 2020 Notes December 31, 2019

ASET ASSETS

ASET LANCAR CURRENT ASSETS Kas dan setara kas 4.401.391.559.413 2e,2s,2v,4,40 3.040.487.103.572 Cash and cash equivalents Piutang usaha 2b,2s,2v,5,40 Trade receivables Pihak ketiga, neto 3.463.656.776.864 3.531.177.696.227 Third parties, net Pihak berelasi 28.360.358.091 2f,8a 41.677.083.452 Related parties Piutang lain-lain 2s,2v,6,40 Other receivables Pihak ketiga 113.554.467.900 122.554.254.390 Third parties Pihak berelasi 2.153.395.940 2f,8b 2.251.088.014 Related parties Aset keuangan lancar lainnya 185.595.252.590 2s,2v,7,40 195.618.535.562 Other current financial assets Persediaan, neto 4.161.626.148.598 2g,9 3.737.976.007.703 Inventories, net Pajak pertambahan nilai dibayar di muka 205.315.450.247 2u 147.588.077.744 Prepaid value added tax Biaya dibayar di muka 52.301.902.647 2h,10 85.488.759.946 Prepaid expenses Aset lancar lainnya 273.158.547.530 11 317.672.371.791 Other current assets

Total Aset Lancar 12.887.113.859.820 11.222.490.978.401 Total Current Assets

ASET TIDAK LANCAR NON-CURRENT ASSETS Aset keuangan tidak lancar lainnya 84.002.251.829 2b, 2v,12,40 63.126.950.000 Other non-current financial assets Investasi pada entitas asosiasi 38.170.340.730 2i,13 27.936.767.060 Investment in associates Aset pajak tangguhan, neto 91.382.422.416 2u 123.162.296.975 Deferred tax assets, net Tagihan restitusi pajak 27.542.339.760 2u,22 52.685.481.719 Claims for tax refund 2h,2j,2k,2l, Aset tetap, neto 8.188.466.673.237 2q,14,18,41 7.666.314.692.908 Fixed assets, net 2d,2l,2m, Aset takberwujud, neto 712.998.045.247 2n,2o,15,41 662.553.056.528 Intangible assets, net Aset hak guna, neto 162.647.441.146 2b,2h,16,41 - Right of use assets, net 2f,2h,2j,2l,2p, Aset tidak lancar lainnya 258.215.195.527 2v,8g,17,40,41 446.456.638.993 Other non-current assets

Total Aset Tidak Lancar 9.563.424.709.892 9.042.235.884.183 Total Non-current Assets

TOTAL ASET 22.450.538.569.712 20.264.726.862.584 TOTAL ASSETS


Catatan atas laporan keuangan konsolidasian terlampir merupakan bagian integral dari laporan

keuangan konsolidasian.

The accompanying notes to the consolidated financial statements form an integral part of these consolidated

financial statements.

2


(lanjutan) Tanggal 30 September 2020 (Belum Diaudit)

(Disajikan dalam Rupiah, kecuali dinyatakan lain)


OF FINANCIAL POSITION (continued) As of September 30, 2020 (Unaudited)

(Expressed in Rupiah, unless otherwise stated)

30 September 2020/ Catatan/ 31 Desember 2019/ September 30, 2020 Notes December 31, 2019

LIABILITAS LIABILITIES

LIABILITAS JANGKA PENDEK CURRENT LIABILITIES Utang bank jangka pendek 406.383.317.320 2v,18,40 149.638.247.114 Short-term bank loans Utang usaha 2s,2v,19,40 Trade payables Pihak ketiga 1.009.797.305.122 1.118.954.747.521 Third parties Pihak berelasi 114.801.681.836 2f,8d 96.905.674.943 Related parties Utang lain-lain 2s,2v,20,40,41 Other payables Pihak ketiga 640.724.122.153 496.089.024.551 Third parties Pihak berelasi - 8e 21.079.800 Related parties Beban akrual 542.790.988.315 2s,2v,21,40 415.650.164.765 Accrued expenses Liabilitas imbalan kerja Short-term employee jangka pendek 115.252.258.258 2t 53.813.903.706 benefits liability Utang pajak 323.700.372.855 2u,22 226.517.164.606 Taxes payable Bagian jangka pendek dari: Current maturities of: Utang bank 182.819.347.128 2v,18,40 19.424.285.946 Bank loans Liabilitas sewa 25.742.071.601 2b,2v,16,40 - Lease liabilities Utang sewa pembiayaan - 2k,2s,2v,14,40 94.512.899 Finance lease payables

Total Liabilitas Jangka Pendek 3.362.011.464.588 2.577.108.805.851 Total Current Liabilities

LIABILITAS JANGKA PANJANG NON-CURRENT LIABILITIES Pinjaman jangka panjang, setelah dikurangi dengan Long-term debts, net of bagian jangka pendek: current maturities: Utang bank 764.207.217.285 2v,18,40 647.647.475.827 Bank loans Liabilitas sewa 70.701.270.367 2b,2v,16,40 - Lease liabilities Utang sewa pembiayaan - 2k,2s,2v,14,40 40.868.940 Finance lease payables Liabilitas pajak tangguhan, neto 247.986.048 2u 241.580.981 Deferred tax liabilities, net Liabilitas imbalan kerja Long-term employee jangka panjang 350.774.105.008 2t 334.105.654.954 benefits liability

Total Liabilitas Jangka Panjang 1.185.930.578.708 982.035.580.702 Total Non-current Liabilities

TOTAL LIABILITAS 4.547.942.043.296 3.559.144.386.553 TOTAL LIABILITIES






3


(lanjutan) Tanggal 30 September 2020 (Belum Diaudit)



OF FINANCIAL POSITION (continued) As of September 30, 2020 (Unaudited)


30 September 2020/ Catatan/ 31 Desember 2019/ September 30, 2020 Notes December 31, 2019

EKUITAS EQUITY

Ekuitas yang Dapat Diatribusikan kepada Equity Attributable to the Pemilik Entitas Induk Owners of the Parent Company Modal saham - nilai nominal Share capital - Rp10 par value Rp10 per saham per share Modal dasar - Authorized - 85.000.000.000 saham 85,000,000,000 shares Modal ditempatkan dan disetor Issued and fully paid - penuh - 46.875.122.110 saham 468.751.221.100 2y,23 468.751.221.100 46,875,122,110 shares Tambahan modal disetor, neto (34.118.673.814) 2d,2y,24 (34.118.673.814) Additional paid-in capital, net Differences arising from Selisih transaksi dengan transaction with kepentingan non-pengendali 27.601.595.876 2c,25 52.932.836.056 non-controlling interests Saldo laba 2b,2z Retained earnings Telah ditentukan penggunaannya 251.029.066.369 23 225.961.420.648 Appropriated Belum ditentukan penggunaannya 16.200.036.200.910 15.135.159.090.134 Unappropriated Modal saham yang diperoleh kembali - 2.175.000 saham pada periode Treasury stock - 2020 (2.063.200.000) 2ac,23 - 2,175,000 shares in 2020 Penghasilan komprehensif lain 2aa Other comprehensive income Selisih kurs atas penjabaran Differences arising from foreign laporan keuangan 135.440.144.947 2c 57.824.661.761 currency translation Laba belum direalisasi Unrealized gain on dari aset keuangan tersedia available-for-sale untuk dijual, neto 77.828.119.925 2v,7,12 56.006.158.259 financial assets, net Kerugian aktuarial atas Actuarial loss on liabilitas imbalan kerja long-term employee jangka panjang, neto (69.390.323.150) 2t (69.390.323.150) benefits liability, net

Sub-total 17.055.114.152.163 15.893.126.390.994 Sub-total

Kepentingan Non-pengendali 847.482.374.253 2c,26 812.456.085.037 Non-controlling Interests

Total Ekuitas 17.902.596.526.416 16.705.582.476.031 Total Equity

TOTAL LIABILITAS DAN TOTAL LIABILITIES AND EKUITAS 22.450.538.569.712 20.264.726.862.584 EQUITY






4

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA LAPORAN LABA RUGI DAN PENGHASILAN

KOMPREHENSIF LAIN KONSOLIDASIAN Untuk Periode yang Berakhir pada Tanggal

30 September 2020 (Belum Diaudit) (Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENT OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME For the Period Ended September 30, 2020

(Unaudited) (Expressed in Rupiah, unless otherwise stated)

Periode yang Berakhir pada Tanggal 30 September/ Period Ended September 30

Catatan/ 2020 Notes 2019

2f,2r,2w,8c

PENJUALAN NETO 17.095.837.856.582 27,28 16.826.807.706.181 NET SALES 2f,2r,2w,8f, BEBAN POKOK PENJUALAN (9.324.489.927.591) 27,29 (9.063.547.052.721) COST OF GOODS SOLD

LABA BRUTO 7.771.347.928.991 7.763.260.653.460 GROSS PROFIT

Beban penjualan (3.987.661.946.154) 2w,27,30 (4.113.228.613.414) Selling expenses General and administrative Beban umum dan administrasi (1.008.202.208.040) 2w,27,31 (955.440.811.344) expenses Beban penelitian Research and development dan pengembangan (217.274.525.680) 2o,2w,27,32 (201.227.452.426) expenses Pendapatan operasi lainnya 105.332.456.700 2j,2s,2w,27,36 42.078.692.095 Other operating income 2j,2s,2u, Beban operasi lainnya (33.429.304.666) 2w,27,35 (43.976.194.893) Other operating expenses Penghasilan bunga 114.856.781.861 2w,27,34 108.636.168.457 Interest income Interest expense and Beban bunga dan keuangan (67.432.810.061) 2w,27,33 (27.520.582.535) financial charges Bagian atas laba Share in gain of the entitas asosiasi 10.233.573.670 2i,2w,13,27 1.681.216.325 associates

LABA SEBELUM BEBAN INCOME BEFORE PAJAK PENGHASILAN 2.687.769.946.621 2.574.263.075.725 INCOME TAX EXPENSE BEBAN PAJAK PENGHASILAN, Neto (615.545.810.277) 2u,2w,22,27 (628.432.340.810) INCOME TAX EXPENSE, Net

LABA PERIODE BERJALAN 2.072.224.136.344 1.945.830.734.915 INCOME FOR THE PERIOD

PENGHASILAN OTHER COMPREHENSIVE KOMPREHENSIF LAIN 2aa INCOME Pos yang tidak akan direklasifikasi Item that will not be reclassified ke laba rugi - - to profit or loss Pos-pos yang akan direklasifikasi Items that will be reclassified ke laba rugi: to profit or loss: Laba belum direalisasi Unrealized gain on dari aset keuangan tersedia available-for-sale untuk dijual, neto 30.150.762.337 2v,7,12 11.179.500.433 financial assets, net Selisih kurs atas penjabaran Differences arising from foreign laporan keuangan 77.615.483.186 2c (13.430.994.865) currency translation

Penghasilan (rugi) komprehensif Other comprehensive lain setelah pajak 107.766.245.523 (2.251.494.432) income (loss) after tax

TOTAL LABA KOMPREHENSIF TOTAL COMPREHENSIVE PERIODE BERJALAN 2.179.990.381.867 1.943.579.240.483 INCOME FOR THE PERIOD






5

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA LAPORAN LABA RUGI DAN PENGHASILAN

KOMPREHENSIF LAIN KONSOLIDASIAN (lanjutan) Untuk Periode yang Berakhir pada Tanggal

30 September 2020 (Belum Diaudit) (Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENT OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME (continued)

For the Period Ended September 30, 2020 (Unaudited)




Laba Periode Berjalan Yang Income For The Period Dapat Diatribusikan Kepada: Attributable To: Pemilik entitas induk 2.027.403.698.697 2w,27 1.915.467.057.370 Owners of the parent company Kepentingan non-pengendali 44.820.437.647 2w,27 30.363.677.545 Non-controlling interests

Total 2.072.224.136.344 1.945.830.734.915 Total

Total Laba Komprehensif Periode Berjalan Yang Total Comprehensive Income Dapat Diatribusikan Kepada: For The Period Attributable To: Pemilik entitas induk 2.135.146.418.149 1.912.535.483.997 Owners of the parent company Kepentingan non-pengendali 44.843.963.718 31.043.756.486 Non-controlling interests

Total 2.179.990.381.867 1.943.579.240.483 Total

Laba per Saham Dasar Basic Earnings per Yang Dapat Diatribusikan Share Attributable to Owners kepada Pemilik Entitas Induk 43,25 2x,23,43 40,86 of the Parent Company


Catatan atas laporan keuangan konsolidasian terlampir merupakan bagian integral

dari laporan keuangan konsolidasian. The accompanying notes to the consolidated financial statements form an integral part of

these consolidated financial statements.

6

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA LAPORAN PERUBAHAN EKUITAS KONSOLIDASIAN

Untuk Periode yang Berakhir pada Tanggal 30 September 2020 (Belum Diaudit)


PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENT OF

CHANGES IN EQUITY For the Period Ended September 30, 2020 (Unaudited)


Ekuitas yang Dapat Diatribusikan kepada Pemilik Entitas Induk/Equity Attributable to the Owners of the Parent Company

Penghasilan Komprehensif Lain/ Other Comprehensive Income

Selisih Kurs Selisih atas Kerugian Transaksi Penjabaran Laba Belum Aktuarial atas Dengan Kepentingan Laporan Direalisasi dari Liabilitas Imbalan Modal Non-pengedali/ Saldo Laba/ Keuangan/ Aset Keuangan Kerja Jangka Ditempatkan dan Differences Retained Earnings Differences Tersedia untuk Panjang, Neto/

Disetor Penuh/ Tambahan Arising from Arising from Dijual, Neto/ Actuarial Loss on Kepentingan Issued and Modal Disetor, Neto/ Transaction with Telah Ditentukan Belum Ditentukan Modal Saham Yang Foreign Unrealized Gains on for Long-term Non-pengendali/ Catatan/ Fully Paid Additional Non-controlling Penggunaannya/ Penggunaannya/ Diperoleh Kembali/ Currency Available-for-Sale Employee Benefits Sub-total/ Non-controlling Total Ekuitas/ Notes Capital Paid-in Capital, Net Interests Appropriated Unappropriated Treasury Stock Translation Financial Assets, Net Liability, Net Sub-total Interests Total Equity

Saldo pada tanggal 31 Desember 2018 468.751.221.100 (34.118.673.814) 46.967.626.117 201.390.130.325 13.871.718.983.242 - 71.460.322.752 42.056.395.763 (44.768.029.424) 14.623.457.976.061 671.136.820.293 15.294.594.796.354 Balance as of December 31, 2018 Saldo laba yang telah ditentukan penggunaannya untuk cadangan umum 23 - - - 24.571.290.323 (24.571.290.323 ) - - - - - - - Appropriation of retained earnings for general reserve Selisih kurs atas penjabaran laporan keuangan 2c - - - - - - - - - - (9.927.246 ) (9.927.246 ) Differences arising from foreign currency translation Setoran modal dari kepentingan non-pengendali entitas anak 25 - - - - - - - - - - 183.708.000.000 183.708.000.000 Additional capital from subsidiaries’ non-controlling interest Akuisisi dari kepentingan non-pengendali 2c,25 - - 5.913.182.937 - - - - - - 5.913.182.937 (41.229.021.201 ) (35.315.838.264) Acquisition of non-controlling interests Penjualan saham kepada kepentingan non-pengendali 25 - - (284.788.410 ) - - - - - - (284.788.410) 2.473.111.563 2.188.323.153 Sale of shares to non-controlling interest Pembagian dividen kas 23 - - - - (1.218.753.174.860 ) - - - - (1.218.753.174.860) (34.090.902.425 ) (1.252.844.077.285) Distribution of cash dividends Realisasi laba dari aset keuangan tersedia untuk dijual - - - - - - - 269.966 - 269.966 - 269.966 Realized gain on available-for-sale financial assets Total laba komprehensif periode 2019 - - - - 1.915.467.057.370 - (13.430.994.865 ) 10.499.421.492 - 1.912.535.483.997 31.043.756.486 1.943.579.240.483 Total comprehensive income for 2019

Saldo pada tanggal 30 September 2019 468.751.221.100 (34.118.673.814) 52.596.020.644 225.961.420.648 14.543.861.575.429 - 58.029.327.887 52.556.087.221 (44.768.029.424) 15.322.868.949.691 813.031.837.470 16.135.900.787.161 Balance as of September 30, 2019

Saldo pada tanggal 31 Desember 2019 468.751.221.100 (34.118.673.814) 52.932.836.056 225.961.420.648 15.135.159.090.134 - 57.824.661.761 56.006.158.259 (69.390.323.150 ) 15.893.126.390.994 812.456.085.037 16.705.582.476.031 Balance as of December 31, 2019 Saldo laba yang telah ditentukan penggunaannya untuk cadangan umum 23 - - - 25.067.645.721 (25.067.645.721 ) - - - - - - - Appropriation of retained earnings for general reserve Selisih kurs atas penjabaran laporan keuangan 2c - - - - - - - - - - (948.080.522 ) (948.080.522 ) Differences arising from foreign currency translation Dilusi dari kepentingan non-pengendali 2c,25 - - (25.331.240.180 ) - - - - - - (25.331.240.180) 25.331.240.180 ) - Dilution of non-controlling interests Pembelian kembali saham 2ac, 23 - - - - - (2.063.200.000 ) - - - (2.063.200.000 - (2.063.200.000) Buy back of Shares Pembagian dividen kas 23 - - - - (937.502.442.200 ) - - - - (937.502.442.200) (33.524.959.418 ) (971.027.401.618) Distribution of cash dividends Dividen atas modal treasury 23 - - - - 43.500.000 - - - - 43.500.000 - 43.500.000 Dividends from treasury stock Realisasi laba dari aset keuangan tersedia untuk dijual - - - - - - - (8.305.274.600 ) - (8.305.274.600) (675.874.742 ) (8.981.149.342) Realized gain on available-for-sale financial assets Total laba komprehensif periode 2020 - - - - 2.027.403.698.697 - 77.615.483.186 30.127.236.266 - 2.135.146.418.149 44.843.963.718 2.179.990.381.867 Total comprehensive income for 2020

Saldo pada tanggal 30 September 2020 468.751.221.100 (34.118.673.814) 27.601.595.876 251.029.066.369 16.200.036.200.910 (2.063.200.000 ) 135.440.144.947 77.828.119.925 (69.390.323.150) 17.055.114.152.163 847.482.374.253 17.902.596.526.416 Balance as of September 30, 2020



konsolidasian.

The accompanying notes to the consolidated financial statements form an integral part of these consolidated financial

statements.

7

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA LAPORAN ARUS KAS KONSOLIDASIAN



PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS

For the Period Ended September 30, 2020 (Unaudited)




ARUS KAS DARI AKTIVITAS CASH FLOWS FROM OPERASI OPERATING ACTIVITIES Penerimaan kas dari pelanggan 18.783.996.342.157 17.840.112.673.873 Cash receipts from customers Pembayaran kas ke pemasok (9.522.918.831.007) (9.364.282.778.810) Cash payments to suppliers Pembayaran kas ke karyawan (2.172.626.980.920) (2.127.684.974.914) Cash payments to employees

Kas yang dihasilkan dari operasi 7.088.450.530.230 6.348.144.920.149 Cash generated from operations Penerimaan tagihan restitusi pajak 19.052.521.188 21.577.624.755 Receipts of claims for tax refund Pembayaran pajak penghasilan (458.173.339.098) (599.567.523.911) Payments for income taxes Pembayaran untuk beban operasi Payments for other operating lainnya, neto (4.126.071.195.141) (4.213.774.413.587) expenses, net

Kas Neto Diperoleh dari Net Cash from Aktivitas Operasi 2.523.258.517.179 1.556.380.607.406 Operating Activities

ARUS KAS DARI AKTIVITAS CASH FLOWS FROM INVESTASI INVESTING ACTIVITIES Penerimaan penghasilan bunga 94.671.754.310 88.600.907.322 Interest income received Pencairan aset keuangan Withdrawal of other current lancar lainnya 29.000.000.000 338.090 financial assets Penerimaan hasil penjualan Proceeds from sale of aset tetap 6.708.620.718 14 8.799.916.600 fixed assets Penerimaan dividen kas - 262.500.000 Cash dividends received Perolehan aset tetap (784.895.534.903) 27 (1.360.718.303.016) Acquisitions of fixed assets Perolehan aset takberwujud (92.832.078.534) (75.896.888.350) Acquisitions of intangible assets Penempatan pada aset Placements in other keuangan lancar lainnya (8.000.000.000) - current financial assets Penempatan pada aset Placements in other keuangan tidak lancar lainnya - (2.132.250.000) non-current financial assets

Kas Neto Digunakan untuk Net Cash Used in Aktivitas Investasi (755.347.238.409) (1.341.083.779.354) Investing Activities

ARUS KAS DARI AKTIVITAS CASH FLOWS FROM PENDANAAN FINANCING ACTIVITIES Penerimaan utang bank Proceeds from jangka pendek 667.995.082.158 38 184.480.362.691 short-term bank loans Penerimaan utang bank Proceeds from long-term jangka panjang 362.000.000.000 38 395.000.000.000 bank loans Penerimaan pelunasan pinjaman Receipt of loan payment dari entitas asosiasi 8.000.571.328 - from an associate Penerimaan setoran modal Receipts of capital contributions saham dari kepentingan non- from subsidiaries’ pengendali entitas anak - 169.988.000.000 non-controlling interests Pembayaran dividen kas: Payments of cash dividends: Perusahaan (937.458.942.200) 23 (1.218.753.174.860) Company Entitas anak (33.524.959.418) (34.090.902.425) Subsidiaries Pembayaran utang bank Payments of short-term jangka pendek (412.633.329.272) 38 (146.635.016.485) bank loans Pembayaran utang bank Payments of long-term jangka panjang (82.045.197.360) 38 (58.623.961.071) bank loans Pembayaran beban bunga (62.526.058.618) 38 (27.083.214.825) Payments of interest expense Pembayaran liabilitas sewa (17.719.132.946) - Payments of lease liabilities Penarikan kembali saham (2.063.200.000) 23 - Buy back of shares Pembayaran utang sewa pembiayaan (140.367.391) 38 (1.140.479.243) Payment of finance lease payables Pemberian pinjaman kepada entitas asosiasi - (7.500.000.000) Loan to an associate

Kas Neto Digunakan untuk Net Cash Used in Aktivitas Pendanaan (510.115.533.719) (744.358.386.218) Financing Activities



konsolidasian.

The accompanying notes to the consolidated financial statement form an integral part of these consolidated financial

statements.

8

PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA LAPORAN ARUS KAS KONSOLIDASIAN (lanjutan)



PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS

(continued) For the Period Ended September 30, 2020

(Unaudited) (Expressed in Rupiah, unless otherwise stated)



KENAIKAN (PENURUNAN) NETO NET INCREASE (DECREASE) IN KAS DAN SETARA KAS 1.257.795.745.051 (529.061.558.166) CASH AND CASH EQUIVALENTS Pengaruh Neto Perubahan Net Effect on Changes in Foreign Kurs pada Kas dan Setara Kas Exchange Rates of Foreign yang Didenominasi dalam Currency Denominated Mata Uang Asing 101.725.393.470 (15.287.742.934) Cash and Cash Equivalents KAS DAN SETARA KAS CASH AND CASH EQUIVALENTS AWAL PERIODE 3.040.487.103.572 3.153.327.557.173 AT BEGINNING OF PERIOD

KAS DAN SETARA KAS CASH AND CASH EQUIVALENTS AKHIR PERIODE * 4.400.008.242.093 2.608.978.256.073 AT END OF PERIOD *

*Komposisi kas dan setara kas Cash and cash equivalents* terdiri dari: consist of: Kas dan setara kas 4.401.391.559.413 4 2.611.412.930.955 Cash and cash equivalents Cerukan (1.383.317.320) 18 (2.434.674.882) Overdrafts

Neto 4.400.008.242.093 2.608.978.256.073 Net

Tambahan informasi arus kas Supplemental cash flows information diungkapkan dalam Catatan 46 is presented in Note 46



CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN

Tanggal 30 September 2020 dan Untuk Periode yang Berakhir pada Tanggal

Tersebut (Belum Diaudit) (Disajikan dalam Rupiah, kecuali dinyatakan lain)

PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES NOTES TO THE CONSOLIDATED

FINANCIAL STATEMENTS As of September 30, 2020 and

For the Period then Ended (Unaudited) (Expressed in Rupiah, unless otherwise stated)

9

1. UMUM 1. GENERAL

a. Pendirian Perusahaan a. Establishment of the Company

PT Kalbe Farma Tbk. (“Perusahaan”) didirikan

di Negara Republik Indonesia, dalam rangka Undang-undang Penanaman Modal Dalam Negeri No. 6 Tahun 1968 yang telah diubah dengan Undang-undang No. 12 Tahun 1970, berdasarkan Akta Notaris Raden Imam Soesatyo Prawirokoesoemo No. 3 pada tanggal 10 September 1966. Akta pendirian ini telah disahkan oleh Menteri Kehakiman Republik Indonesia dengan Surat Keputusan No. J.A.5/72/23 tanggal 12 September 1967 dan diumumkan dalam Tambahan No. 234, Berita Negara Republik Indonesia No. 102 pada tanggal 22 Desember 1967. Anggaran dasar Perusahaan telah mengalami beberapa kali perubahan, terakhir dengan Akta Notaris Rusnaldy, S.H., No. 41 tanggal 22 Mei 2019, mengenai perubahan maksud dan tujuan serta kegiatan usaha Perusahaan untuk disesuaikan dengan Klasifikasi Baku Lapangan Usaha Indonesia Tahun 2017. Perubahan ini telah diterima oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-0032248.AH.01.02 tanggal 21 September 2019.

PT Kalbe Farma Tbk. (the “Company”) was established in the Republic of Indonesia, within the framework of the Domestic Capital Investment Law No. 6 Year 1968, as amended by Law No. 12 Year 1970, based on Notarial Deed No. 3 of Raden Imam Soesatyo Prawirokoesoemo dated September 10, 1966. The Deed of establishment was approved by the Ministry of Justice of the Republic of Indonesia in its Decision Letter No. J.A.5/72/23 dated September 12, 1967 and was published in Supplement No. 234 of State Gazette No. 102 dated December 22, 1967. The Company’s Articles of Association have been amended several times, the latest amendment of which was drawn up in Notarial Deed No. 41 of Rusnaldy, S.H., dated May 22, 2019, regarding the changes in the Company’s purpose, objectives and scope of activities to comply with the Indonesian Standard Industrial Classification Year 2017. The amendment had been accepted by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-0032248.AH.01.02 dated September 21, 2019.

Seperti yang dinyatakan dalam Anggaran

Dasarnya, ruang lingkup kegiatan Perusahaan meliputi, antara lain usaha dalam bidang farmasi, perdagangan dan perwakilan. Saat ini, Perusahaan terutama bergerak dalam bidang pengembangan, pembuatan dan perdagangan sediaan farmasi termasuk obat untuk manusia dan hewan serta produk konsumsi kesehatan. Perusahaan memulai operasi komersial pada tahun 1966.

As stated in its Articles of Association, the scope of activities of the Company comprises, among others, pharmaceutical, trading and representative. Currently, the Company is primarily engaged in the development, manufacturing and trading of pharmaceutical products including human and veterinary medicines and consumer health products. The Company started its commercial operations in 1966.

Perusahaan berkedudukan di Jakarta, dimana

kantor pusat berada di Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Cempaka Putih, Jakarta 10510 sedangkan fasilitas pabriknya berlokasi di Kawasan Industri Delta Silicon, Jl. M.H. Thamrin, Blok A3-1, Lippo Cikarang, Bekasi, Jawa Barat.

The Company is domiciled in Jakarta, with its head office located at KALBE Building Jl. Let. Jend. Suprapto Kav. 4, Cempaka Putih, Jakarta 10510, while its production plant is located at Kawasan Industri Delta Silicon, Jl. M.H. Thamrin, Block A3-1, Lippo Cikarang, Bekasi, West Java.









10

1. UMUM (lanjutan) 1. GENERAL (continued)

b. Penawaran Umum Saham Perusahaan dan

Kegiatan Perusahaan Lainnya b. Public Offering of the Company’s Shares

and Other Corporate Actions

Ringkasan kegiatan Perusahaan (corporate actions) yang mempengaruhi efek yang diterbitkan Perusahaan sejak tanggal penawaran umum perdana sampai dengan tanggal 30 September 2020 adalah sebagai berikut:

A summary of the Company’s corporate actions that affected the issued shares of the Company from the date of the initial public offering of its shares up to September 30, 2020 is as follows:

Jumlah Saham/ Number of Tanggal/ Kegiatan Perusahaan Shares Date Nature of Corporate Actions

Penawaran umum perdana dan pencatatan sebagian saham 30 Juli 1991/ Initial public offering and partial listing of Perusahaan 20.000.000 July 30, 1991 the Company’s shares Pencatatan saham Perusahaan 30.000.000 Listing of the Company’s shares in Bursa Efek Jakarta 23 April 1992/ Jakarta Stock Exchange (sekarang Bursa Efek Indonesia) April 23, 1992 (currently Indonesia Stock Exchange) Bursa Efek Surabaya 22 Mei 1992/ Surabaya Stock Exchange (sekarang Bursa Efek Indonesia) May 22, 1992 (currently Indonesia Stock Exchange) Pembagian saham bonus 50.000.000 Distribution of bonus shares Bursa Efek Surabaya 10 November 1992/ Surabaya Stock Exchange (sekarang Bursa Efek Indonesia) November 10, 1992 (currently Indonesia Stock Exchange) Bursa Efek Jakarta 17 November 1992/ Jakarta Stock Exchange (sekarang Bursa Efek Indonesia) November 17, 1992 (currently Indonesia Stock Exchange) Penawaran umum terbatas 8.000.000 4 Mei 1993/ Rights issue May 4, 1993 Pembagian saham bonus 75.600.000 Distribution of bonus shares Bursa Efek Surabaya 15 Juli 1994/ Surabaya Stock Exchange (sekarang Bursa Efek Indonesia) July 15, 1994 (currently Indonesia Stock Exchange) Bursa Efek Jakarta 18 Juli 1994/ Jakarta Stock Exchange (sekarang Bursa Efek Indonesia) July 18, 1994 (currently Indonesia Stock Exchange) Pembagian dividen saham 32.400.000 Distribution of share dividends Bursa Efek Surabaya 15 Juli 1994/ Surabaya Stock Exchange (sekarang Bursa Efek Indonesia) July 15, 1994 (currently Indonesia Stock Exchange) Bursa Efek Jakarta 18 Juli 1994/ Jakarta Stock Exchange (sekarang Bursa Efek Indonesia) July 18, 1994 (currently Indonesia Stock Exchange) Perubahan nilai nominal saham dari Change in the nominal value of shares Rp1.000 menjadi Rp500 per 7 Oktober 1996/ from Rp1,000 to Rp500 per share saham (stock split) 216.000.000 October 7, 1996 (stock split)

Perubahan nilai nominal saham dari Change in the nominal value of shares Rp500 menjadi Rp100 per saham 24 Agustus 1999/ from Rp500 to Rp100 per share (stock split) 1.728.000.000 August 24, 1999 (stock split) 6 Desember 2000/ Pembagian saham bonus 1.900.800.000 December 6, 2000 Distribution of bonus shares

Perubahan nilai nominal saham dari Change in the nominal value of shares Rp100 menjadi Rp50 per saham 19 Desember 2003/ from Rp100 to Rp50 per share (stock split) 4.060.800.000 December 19, 2003 (stock split)









11

1. UMUM (lanjutan) 1. GENERAL (continued) b. Penawaran umum saham Perusahaan dan

kegiatan Perusahaan lainnya (lanjutan) b. Public offering of the Company’s shares

and other corporate actions (continued) Jumlah Saham/ Number of Tanggal/ Kegiatan Perusahaan Shares Date Nature of Corporate Actions

Tambahan penempatan saham sehubungan dengan 16 Desember 2005/ Additional issuance of shares in penggabungan usaha 2.034.414.422 December 16, 2005 connection with merger transaction

Perubahan nilai nominal saham dari Change in the nominal value of shares Rp50 menjadi Rp10 per saham 5 Oktober 2012/ from Rp50 to Rp10 per share (pemecahan saham) 40.624.057.688 October 5, 2012 (stock split)

Penarikan kembali modal ditempatkan Withdrawal of issued and fully paid shares dan disetor penuh sebesar saham 31 Oktober 2013/ capital which have been reacquired yang dibeli kembali (modal treasuri) (3.904.950.000) October 31, 2013 as treasury stock

Total 46.875.122.110 Total

c. Dewan Komisaris dan Dewan Direksi,

Komite Audit, Sekretaris Perusahaan dan Karyawan

c. Boards of Commissioners and Directors, Audit Committee, Corporate Secretary and Employees

Susunan Dewan Komisaris dan Dewan Direksi

Perusahaan adalah sebagai berikut: The members of the Company’s Boards of

Commissioners and Directors are as follows:

30 September, 2020/ September 30, 2020

31 Desember 2019/ December 31, 2019

Dewan Komisaris Board of Commissioners Presiden Komisaris : Bernadette Ruth Irawati

Setiady Bernadette Ruth Irawati

Setiady : President Commissioner

Komisaris : Santoso Oen Santoso Oen : Commisioner Komisaris : Ferdinand Aryanto Ferdinand Aryanto : Commisioner Komisaris : Ronny Hadiana Ronny Hadiana : Commisioner Komisaris Independen : Lucky Surjadi Slamet Lucky Surjadi Slamet : Independent Commisioner Komisaris Independen : Lilis Halim Lilis Halim : Independent Commisioner Komisaris Independen : Adi Harsono Farid Anfasa Moeloek : Independent Commisioner Dewan Direksi Board of Directors Presiden Direktur : Vidjongtius Vidjongtius : President Director Direktur : Bernadus Karmin

Winata Bernadus Karmin

Winata : Director

Direktur : Ongkie Tedjasurja Ongkie Tedjasurja : Director Direktur : Bujung Nugroho Bujung Nugroho : Director Direktur : Djonny Hartono

Tjahyadi Djonny Hartono

Tjahyadi : Director

Direktur : Sie Djohan Sie Djohan : Director









12


c. Dewan Komisaris dan Dewan Direksi, Komite Audit, Sekretaris Perusahaan dan Karyawan (lanjutan)

c. Boards of Commissioners and Directors, Audit Committee, Corporate Secretary and Employees (continued)

Susunan Komite Audit dan Sekretaris Perusahaan adalah sebagai berikut:

The composition of the Company’s Audit Committee and Corporate Secretary is as follows:

Komite Audit 30 September, 2020/

September 30, 2020 31 Desember 2019/

December 31, 2019

Audit Committee

Ketua : Adi Harsono Lucky Surjadi Slamet : Chairman Anggota : Haryo Suparmun Kai Arief Iman Selomulya : Member Anggota : Dianawati Sugiarto Kurniawan Tedjo : Member

Sekretaris Perusahaan 30 September, 2020/

September 30, 2020 31 Desember 2019/

December 31, 2019

Corporate Secretary Sekretaris Perusahaan Lukito Kurniawan Gozali Bernadus Kamin Winata Corporate Secretary

Perusahaan memiliki unit audit internal yang bertanggung jawab langsung kepada Presiden Direktur untuk melakukan fungsi audit terhadap kegiatan operasional dan pelaporan keuangan yang dilakukan Perusahaan.

The Company has an internal audit unit which is directly responsible to the President Director, in performing its audit functions on the operations and financial reporting performed by the Company.

Pada tanggal 30 September 2020 dan 31 Desember 2019, Perusahaan dan entitas anaknya (secara kolektif disebut sebagai “Grup”) mempunyai karyawan tetap masing-masing sebanyak 12.161 dan 12.427 karyawan (tidak diaudit).

As of September 30, 2020 and December 31, 2019, the Company and its subsidiaries (collectively referred to as “the Group”) have a combined total of 12,161 and 12,427 permanent employees, respectively (unaudited).

d. Struktur Perusahaan dan Entitas Anak d. Corporate Structure and Subsidiaries

Entitas anak yang secara langsung dan tidak

langsung dimiliki Perusahaan dengan pemilikan saham lebih dari 50% adalah sebagai berikut:

The subsidiaries, in which the Company has control and directly or indirectly owns at least 50% of the voting shares, are as follows:

Total Aset Sebelum Eliminasi Persentase Pemilikan (Dalam Jutaan)/

Kegiatan Mulai Efektif/ Total Assets Usaha/ Beroperasi Effective Percentage Before Elimination Produk/ Komersial/ of Ownership (In Millions) Nama Nature of Commencement

Entitas Anak/ Business Tempat of 30 September 2020/ 31 Desember 2019/

Names of Activities/ Kedudukan/ Commercial September 30, 2020 December 31, 2019 30 September 2020/ 31 Desember 2019/ Subsidiaries Products Domicile Operations % % September 30, 2020 December 31, 2019

Farmasi:/ Pharmaceutical: PT Bintang Toedjoe Farmasi dan Jakarta 1949 100,00 100,00 1.914.175 1.350.176 - Bintang Obat Tradisional/ Toedjoe (1) Pharmaceutical and

Traditional Medicine

PT Hexpharm Jaya Farmasi/ Bekasi 1995 100,00 100,00 743.467 674.328

Laboratories Pharmaceutical - Hexpharm (1)









13


d. Struktur Perusahaan dan Entitas Anak (lanjutan)

d. Corporate Structure and Subsidiaries (continued)





Farmasi:/ (lanjutan) Pharmaceutical: (continued)

PT Saka Farma Farmasi/ Jakarta 1997 100,00 100,00 721.000 593.280 Laboratories Pharmaceutical - Saka (1) PT Finusolprima Farma Farmasi/ Bekasi 1981 100,00 100,00 491.797 462.051 Internasional Pharmaceutical - Finusolprima (1) PT Bifarma Adiluhung Jasa Jakarta 1997 100,00 100,00 31.449 23.188 - Bifarma (1) Pemeriksaan Kesehatan/ Health Screening Service Innogene Kalbiotech Agen dan Singapura/ 2004 93,34 93,34 85.251 96.893 Pte. Ltd. Perwakilan Singapore

- Innogene (1) Produk Bioteknologi/ Agent and Representative for Biotechnology Products PT Dankos Farma Farmasi/ Jakarta 2006 100,00 100,00 509.210 578.699 - Danfar (1) (e) Pharmaceutical PT Pharma Metric Labs. Jasa Jakarta 2006 81,64 81,64 27.032 21.134 - PML (1) Pengujian Laboratorium Penelitian dan Pengembangan Ilmu Pengetahuan/ Research and Development of Science Laboratory

Testing Service PT Kalbio Global Farmasi/ Bekasi 2019 100,00 100,00 980.791 866.308 Medika Pharmaceutical - KGM (1) PT KalGen DNA Penjualan Jakarta 2013 60,00 60,00 12.403 10.301 - KalGen (4) Alat Laboratorium, Farmasi dan Kedokteran/ Trading of Laboratory Equipment and Medical Devices









14








Farmasi:/ (lanjutan) Pharmaceutical: (continued)

PT Kalbe Genexine Farmasi dan Jakarta -**) 60,00 60,00 557.197 563.584 Biologics Penelitian dan - KGB (1) (b) Pengembangan Bioteknologi/ Pharmaceutical and Research and Development Biotechnology

PT Innolab Sains Pelayanan Jakarta 2016 60,00 60,00 90.964 46.697 Internasional Kesehatan/ - ISI (6) Health Service

PT Global Onkolab Farma Farmasi/ Jakarta 2019 100,00 100,00 102.204 101.485 - GOF (1) (d) Pharmaceutical Kalbe Myanmar Farmasi/ Myanmar -***) 100,00 100,00 308.682 206.909 Company Ltd. Pharmaceutical - KMC (3) (f)

PT Forsta Kalmedic Industri Jakarta -*) 92,47 92,47 25.606 13.095 Global Peralatan Kedokteran

- FKG (9) (i) dan Kedokteran Gigi serta Jasa Kalibrasi/ Medical and Dental Equipment Industry and Calibration Service

Kalbe Lanka Pvt. Ltd. Farmasi/ Srilanka -*) 100,00 100,00 5.461 - - KLK (3) (k) Pharmaceutical

PT Kalbe Biotek Perusahaan Induk Jakarta -****) 100,00 - - - Indonesia dan Konsultan - KBI (1) (m) Manajemen/ Holding Company and Management Consultant PT Agroveta Husada Industri Obat Hewan/ Jakarta -****) 100,00 - - - Dharma Veterinary Medicine - AHD (1) (o) Industry

Makanan dan Minuman Kesehatan:/ Health Foods and Beverages: PT Sanghiang Perkasa Makanan Jakarta 1982 100,00 100,00 3.943.783 3.633.336 - Sanghiang (1) dan Minuman Kesehatan/ Health Food and Beverages

PT Kalbe Morinaga Pengolahan Jakarta 2007 70,00 70,00 357.016 355.696 Indonesia Produk Susu/ - KMI (5) (n) Milk Products Processing

PT Hale Minuman Bogor 2012 100,00 100,00 89.859 122.195 International Kesehatan/ - Hale (1) Health Beverages









15








Makanan dan Minuman Kesehatan:/ (lanjutan) Health Foods and Beverages: (continued) PT Kalbe Milko Pengolahan Bogor 2016 51,00 51,00 165.739 175.199 Indonesia Produk Susu/ - KAMI (5) (j) Milk Products Processing

PT Global Vita Nutritech Industri Jakarta 2018 100,00 100,00 41.233 36.286 - GVN (5) Premix/

Premix Industry

Distribusi dan Logistik:/ Distribution and Logistic: PT Enseval Putera Distribusi Jakarta 1993 92,47 92,47 8.923.731 8.704.959 Megatrading Tbk. Obat-Obatan,

- EPMT (1) Barang Konsumsi, Peralatan Kesehatan, Kosmetik dan Barang Dagang Lainnya/ Distribution of Pharmaceutical Products, Consumer Products, Medical Equipment, Cosmetics and Other

Trading Products PT Tri Sapta Jaya Distribusi Produk Jakarta 1980 92,47 92,47 579.360 615.883 - TSJ (2) Obat-obatan

dan Peralatan Kesehatan/

Distribution of Pharmaceutical Products and Medical Equipment

PT Millenia Dharma Klinik Jakarta 2003 92,47 92,47 11.433 8.316 Insani Pelayanan

- MDI (2) Kesehatan/ Health Care Clinics

PT Enseval Medika Perdagangan Jakarta 2008 92,47 92,47 719.675 736.304 Prima Peralatan dan

- EMP (2) Perlengkapan Kesehatan dan Laboratorium/ Trading of Medical and Laboratory Equipment and Supplies









16








Distribusi dan Logistik:/ (lanjutan) Distribution and Logistic: (continued) PT Global Chemindo Penjualan Jakarta 2008 92,47 92,47 813.956 772.891 Megatrading Bahan Baku

- GCM (2) Obat-obatan/ Trading of Raw Materials for Pharmaceutical Products PT Global Karsa Perdagangan Besar Jakarta -**) 92,47 92,47 3.166 3.110 Medika Farmasi,

- GKM (8) (g) Alat Kesehatan, Makanan dan Minuman Lainnya/ Wholesale Trading of Pharmaceuticals, Medical Equipment, Other Food and Beverages PT Renalmed Tiara Perdagangan Jakarta 2008 91,31 91,31 144.327 147.444 Utama Besar Mesin,

- RTU (2) Peralatan dan Barang Habis Pakai untuk Terapi Cuci Darah/ Wholesale Trading of Machinery, Equipment and Consumable Products for Hemodialysis Therapy

Kalbe Vision Pte. Ltd. Pengembangan, Singapura/ 2008 100,00 100,00 20.213 19.929 - KV (1) Produksi, Singapore

Pemasaran dan Distribusi Produk Kesehatan Mata/ Development, Production, Marketing and Distribution of Opthalmic Products

Kalbe International Pemasaran Singapura/ 2007 100,00 100,00 994.209 741.204 Pte. Ltd. Produk Singapore

- KI (1) (h) Farmasi, Kesehatan

dan Nutrisi/ Wholesale of Pharmaceutical, Consumer Health and Nutrition Products









17








Distribusi dan Logistik:/ (lanjutan) Distribution and Logistic: (continued) Asiawide Kalbe Pemasaran Filipina/ 2010 50,00 50,00 14.537 13.173 Philippines, Inc. dan Distribusi Philippines

- AKPI (3) Minuman Energi ‘Ready-to-Drink’/ Marketing and Distribution of Energy Beverages in a Ready-to-Drink Format PT Karsa Lintas Jasa E-Commerce, Jakarta 2013 100,00 100,00 278.781 228.156 Buwana Media Online

- KLB (1) (a) dan Layanan Antar/ E-Commerce, Online Media and Home Delivery Services

Kalbe Malaysia Pemasaran Malaysia 2014 100,00 100,00 33.016 44.773 Sdn., Bhd. Produk

- Kalbe Malaysia Farmasi (3) dan Kesehatan/ Wholesale of Pharmaceutical and Medical Products PT Medika Renal Klinik Cuci Darah, Jakarta 2016 92,47 92,47 33.056 34.303 Citraprima Perdagangan Barang

- MRC (2) Habis Pakai untuk Terapi Cuci Darah/

Hemodialysis Clinic, Trading of Consumable Products for

Hemodialysis Therapy PT Medika Komunika Jasa E-Commerce, Jakarta 2016 64,29 50,00 29.979 22.768 Teknologi Web Portal dan

- MKT (7) (c) Media Online/ E-Commerce,

Web Portal and Online Media Services PT Cakra Radha Jasa E-Commerce, Jakarta 2017 100,00 100,00 144.658 127.605 Mustika Web Portal dan

- CRM (7) Pemasaran Digital/ E-Commerce,

Web Portal and Digital Marketing Services









18








Distribusi dan Logistik:/ (lanjutan) Distribution and Logistic: (continued) PT Karya Hasta Jasa E-Commerce, Jakarta 2017 100,00 100,00 28.306 26.916 Dinamika Web Portal dan

- KHD (7) Layanan Antar/ E-Commerce,

Web Portal and Home Delivery Services Kalbe Global Pte. Ltd. Perusahaan Induk/ Singapura/ 2016 100,00 100,00 34.299 35.799

- KG (1) Holding Company Singapore

PT Emos Global Digital Perdagangan dan Jakarta 2020 95,86 97,36 31.161 - - EGD (2) (l) Usaha Jasa Informasi

melalui Portal Web dan/atau Platform Digital/ Trading and Business Information Services through Web Portals and/or Digital Platforms

*) Sampai dengan tanggal 30 September 2020, FKG dan KLK masih dalam tahap proses pengurusan ijin operasional.

*) Up to September 30, 2020, FKG and KLK are still in the process of obtaining their operating licenses.

**) Sampai dengan tanggal 30 September 2020, KGB dan GKM

belum memulai kegiatan usaha komersial. **) Up to September 30, 2020, KGB and GKM have not

commenced their commercial operations. ***) Sampai dengan tanggal 30 September 2020, KMC masih

dalam proses pembangunan gedung pabrik. ***) Up to September 30, 2020, KMC is still in the process of

constructing its factory building. ****) Pada tanggal 30 September 2020, belum ada setoran modal

di KBI dan AHD. ****) As of September 30, 2020, no share capital has been

injected in KBI and AHD.

Entitas anak yang dimiliki secara langsung oleh: The subsidiaries are directly owned by: (1) Perusahaan (1) Company

(2) EPMT (2) EPMT (3) KI (3) KI (4) Bifarma (4) Bifarma (5) Sanghiang (5) Sanghiang (6) KGM (6) KGM (7) KLB (7) KLB (8) GCM (8) GCM (9) EMP (9) EMP









19




(a) Berdasarkan Akta Notaris Ny. Elly Puspita

Sunarya, S.H., No. 68 tanggal 8 Februari 2018, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KLB dari Rp150.000.000.000 menjadi Rp158.000.000.000, yang telah ditempatkan dan disetor penuh oleh Sanghiang dan Bifarma. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0066595 tanggal 14 Februari 2018.

(a) Based on Notarial Deed No. 68 of Mrs. Elly Puspita Sunarya, S.H., dated February 8, 2018, the shareholders agreed to increase the issued and fully paid share capital of KLB from Rp150,000,000,000 to Rp158,000,000,000, which have been issued and fully paid by Sanghiang and Bifarma. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0066595 dated February 14, 2018.

Berdasarkan Akta Notaris Tjong

Trisnawati, S.H., No. 2 tanggal 18 September 2018, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KLB dari Rp158.000.000.000 menjadi Rp161.000.000.000, yang telah ditempatkan dan disetor penuh oleh Sanghiang dan Bifarma. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia melalui Surat Keputusan No. AHU-AH.01.03-0245774 tanggal 25 September 2018.

Based on Notarial Deed No. 2 of Tjong Trisnawati, S.H., dated September 18, 2018, the shareholders agreed to increase the issued and fully paid share capital of KLB from Rp158,000,000,000 to Rp161,000,000,000, which have been issued and fully paid by Sanghiang and Bifarma. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0245774 dated September 25, 2018.

Berdasarkan pernyataan keputusan

para pemegang saham KLB yang ditandatangani pada tanggal 1 Oktober 2019 dan diaktakan dalam Akta Notaris Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 14 tanggal 28 Oktober 2019, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KLB dari Rp161.000.000.000 menjadi Rp163.000.000.000, yang telah ditempatkan dan disetor penuh oleh Sanghiang dan Bifarma. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0356019 tanggal 6 November 2019.

Based on KLB’s shareholders’ statement of decree which was signed on October 1, 2019 and covered by Notarial Deed No. 14 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated October 28, 2019, the shareholders agreed to increase the issued and fully paid share capital of KLB from Rp161,000,000,000 to Rp163,000,000,000, which have been issued and fully paid by Sanghiang and Bifarma. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0356019 dated November 6, 2019.









20




(a) Berdasarkan Akta Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 8 tanggal 16 Juni 2020, para pemegang saham sepakat untuk meningkatkan modal dasar KLB dari Rp200.000.000.000 menjadi Rp851.000.000.000 serta meningkatkan modal ditempatkan dan disetor penuh KLB dari Rp163.000.000.000 menjadi Rp213.000.000.000, yang telah ditempatkan dan disetor penuh seluruhnya oleh Sanghiang. Dengan perubahan tersebut, persentase kepemilikan Sanghiang di KLB menjadi 99,96%. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0253337 tanggal 18 Juni 2020.

(a) Based on Notarial Deed No. 8 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated June 16, 2020, the shareholders agreed to increase the authorized capital of KLB from Rp200,000,000,000 to Rp851,000,000,000 and also to increase the issued and fully paid share capital of KLB from Rp163,000,000,000 to Rp213,000,000,000, which has been issued and fully paid by Sanghiang. With the aforesaid change, the percentage of ownership of Sanghiang in KLB is 99.96%. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0253337 dated June 18, 2020.

Berdasarkan Akta Jual Beli Saham Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 36 tanggal 29 September 2020, Perusahaan dan Sanghiang sepakat untuk menjual seluruh saham KLB yang dimiliki oleh Sanghiang kepada Perusahaan. Dengan perubahan tersebut, persentase kepemilikan Perusahaan dan Bifarma di KLB menjadi masing-masing sebesar 99,96% dan 0,04%.

Based on the Deed of Sale and Purchase of Shares No. 36 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated September 29, 2020, the Company and Sanghiang agreed to sell shares of KLB owned by Sanghiang to the Company. With the aforesaid change, the percentage of ownership of the Company and Bifarma in KLB is 99.96% and 0.04%, respectively.

(b) Berdasarkan pernyataan keputusan para pemegang saham KGB yang ditandatangani pada tanggal 21 Mei 2018 dan diaktakan dalam Akta Notaris Sri Buena Brahmana, S.H., M.Kn., No. 45 tanggal 7 September 2018, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KGB dari Rp61.000.000.000 menjadi Rp91.105.000.000, yang telah ditempatkan dan disetor penuh oleh Perusahaan dan Genexine Inc., Korea. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0218105 tanggal 3 Juli 2018.

(b) Based on KGB’s shareholders’ statement of decree which was signed on May 21, 2018 and covered by Notarial Deed No. 45 of Sri Buena Brahmana, S.H., M.Kn., dated September 7, 2018, the shareholders agreed to increase the issued and fully paid share capital of KGB from Rp61,000,000,000 to Rp91,105,000,000, which have been issued and fully paid by the Company and Genexine Inc., Korea. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0218105 dated July 3, 2018.









21




(b) Berdasarkan pernyataan keputusan para pemegang saham KGB yang ditandatangani pada tanggal 3 Desember 2018 dan diaktakan dalam Akta Notaris Sri Buena Brahmana, S.H., M.Kn., No. 127 tanggal 19 Desember 2018, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KGB dari Rp91.105.000.000 menjadi Rp128.105.000.000, yang telah ditempatkan dan disetor penuh oleh Perusahaan dan Genexine Inc., Korea. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0025074 tanggal 15 Januari 2019.

(b) Based on KGB’s shareholders’ statement of decree which was signed on December 3, 2018 and covered by Notarial Deed No. 127 of Sri Buena Brahmana, S.H., M.Kn., dated December 19, 2018, the shareholders agreed to increase the issued and fully paid share capital of KGB from Rp91,105,000,000 to Rp128,105,000,000, which have been issued and fully paid by the Company and Genexine Inc., Korea. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0025074 dated January 15, 2019.

Berdasarkan pernyataan keputusan para pemegang saham KGB yang ditandatangani pada tanggal 22 Juli 2019 dan diaktakan dalam Akta Notaris Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 12 tanggal 14 Agustus 2019, para pemegang saham sepakat untuk meningkatkan modal dasar KGB dari Rp130.000.000.000 menjadi Rp1.000.000.000.000 serta meningkatkan modal ditempatkan dan disetor penuh KGB dari Rp128.105.000.000 menjadi Rp270.255.000.000, yang telah ditempatkan dan disetor penuh oleh Perusahaan dan Genexine Inc., Korea. Perubahan tersebut telah disetujui oleh Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU.0054062.AH.01.02 tanggal 20 Agustus 2019.

Based on KGB’s shareholders’ statement of decree which was signed on July 22, 2019 and covered by Notarial Deed No. 12 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated August 14, 2019, the shareholders agreed to increase the authorized share capital of KGB from Rp130,000,000,000 to Rp1,000,000,000,000 and also increase the issued and fully paid share capital of KGB from Rp128,105,000,000 to Rp270,255,000,000, which have been issued and fully paid by the Company and Genexine Inc., Korea. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU.0054062.AH.01.02 dated August 20, 2019.

Berdasarkan pernyataan keputusan para pemegang saham KGB yang ditandatangani pada tanggal 27 Agustus 2019 dan diaktakan dalam Akta Notaris Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 8 tanggal 9 September 2019, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KGB dari Rp270.255.000.000 menjadi Rp411.665.000.000, yang telah ditempatkan dan disetor penuh oleh Perusahaan dan Genexine Inc., Korea. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0335838 tanggal 23 September 2019.

Based on KGB’s shareholders’ statement of decree which was signed on August 27, 2019 and covered by Notarial Deed No. 8 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated September 9, 2019, the shareholders agreed to increase the issued and fully paid share capital of KGB from Rp270,255,000,000 to Rp411,665,000,000, which have been issued and fully paid by the Company and Genexine Inc., Korea. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0335838 dated September 23, 2019.









22




(b) Berdasarkan pernyataan keputusan para pemegang saham KGB yang ditandatangani pada tanggal 11 September 2019 dan diaktakan dalam Akta Notaris Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 3 tanggal 3 Oktober 2019, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh KGB dari Rp411.665.000.000 menjadi Rp553.075.000.000, yang telah ditempatkan dan disetor penuh oleh Perusahaan dan Genexine Inc., Korea. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0340923 tanggal 4 Oktober 2019.

(b) Based on KGB’s shareholders’ statement of decree which was signed on September 11, 2019 and covered by Notarial Deed No. 3 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated October 3, 2019, the shareholders agreed to increase the issued and fully paid share capital of KGB from Rp411,665,000,000 to Rp553,075,000,000, which have been issued and fully paid by the Company and Genexine Inc., Korea. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0340923 dated October 4, 2019.

(c) Berdasarkan Akta Notaris Ny. Elly Puspita Sunarya, S.H., No. 8 tanggal 3 April 2018, para pemegang saham sepakat untuk meningkatkan modal dasar MKT dari Rp109.500.000.000 menjadi Rp250.000.000.000 serta meningkatkan modal ditempatkan dan disetor penuh dari Rp51.125.000.000 menjadi Rp63.000.000.000 melalui penerbitan 190 saham baru seri B dengan nominal seluruhnya sebesar Rp11.875.000.000, yang telah ditempatkan dan disetor penuh oleh PT Kreatif Media Karya. Dengan perubahan tersebut, persentase kepemilikan KLB di MKT menjadi 50%. Akta perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia melalui Surat Keputusan No. AHU-0007426.AH.01.02 tanggal 3 April 2018.

(c) Based on Notarial Deed of Ny. Elly Puspita Sunarya, S.H., No. 8 dated April 3, 2018, the shareholders agreed to increase the authorized capital of MKT from Rp109,500,000,000 to Rp250,000,000,000 and also increase the issued and fully paid share capital from Rp51,125,000,000 to Rp63,000,000,000 by issuing 190 new shares of serial B with nominal value of Rp11,875,000,000, which has been issued and fully paid by PT Kreatif Media Karya. With the aforesaid change, the percentage of ownership of KLB in MKT is 50%. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-0007426.AH.01.02 dated April 3, 2018.

Berdasarkan Akta Notaris Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 9 tanggal 16 Juni 2020, para pemegang saham sepakat untuk meningkatkan modal dasar MKT dari Rp250.000.000.000 menjadi Rp452.000.000.000 serta meningkatkan modal ditempatkan dan disetor penuh dari Rp63.000.000.000 menjadi Rp113.000.000.000 melalui penerbitan 800 saham baru seri B dengan nominal seluruhnya sebesar Rp50.000.000.000, yang telah ditempatkan dan disetor penuh seluruhnya oleh KLB. Dengan perubahan tersebut, persentase kepemilikan KLB di MKT menjadi 64,29%. Akta perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia melalui Surat Keputusan No. AHU-AH.01.03-0255348 tanggal 22 Juni 2020.

Based on Notarial Deed of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 9 dated June 16, 2020, the shareholders agreed to increase the authorized capital of MKT from Rp250,000,000,000 to Rp452,000,000,000 and also increase the issued and fully paid share capital from Rp63,000,000,000 to Rp113,000,000,000 by issuing 800 new shares of serial B with nominal value of Rp50,000,000,000, which has been issued and fully paid by KLB. With the aforesaid change, the percentage of ownership of KLB in MKT is 64.29%. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0255348 dated June 22, 2020.









23




(d) Berdasarkan Akta Notaris Sri Buena

Brahmana, S.H., M.Kn., No. 13 tanggal 15 Januari 2018, para pemegang saham sepakat untuk meningkatkan modal dasar GOF dari Rp500.000.000 menjadi Rp40.000.000.000 serta meningkatkan modal ditempatkan dan disetor penuh dari Rp300.000.000 menjadi Rp30.300.000.000, yang telah ditempatkan dan disetor penuh oleh Danfar dan Finusolprima. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-0003097.AH.01.02 tanggal 9 Februari 2018.

(d) Based on Notarial Deed No. 13 of Sri Buena Brahmana S.H., M.Kn., dated January 15, 2018, the shareholders agreed to increase the authorized share capital of GOF from Rp500,000,000 to Rp40,000,000,000 and also increase the issued and fully paid share capital from Rp300,000,000 to Rp30,300,000,000, which have been issued and fully paid by Danfar and Finusolprima. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-0003097.AH.01.02 dated February 9, 2018.

Berdasarkan Akta Notaris Fenny Sugiharto,

S.H., No. 7, tanggal 3 Juli 2018, para pemegang saham sepakat untuk meningkatkan modal dasar GOF dari Rp40.000.000.000 menjadi Rp106.000.000.000 serta meningkatkan modal ditempatkan dan disetor penuh dari Rp30.300.000.000 menjadi Rp96.300.000.000, yang telah ditempatkan dan disetor penuh oleh Danfar dan Finusolprima. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-0014334.AH.01.02 tanggal 16 Juli 2018.

Based on Notarial Deed No. 7 of Fenny Sugiharto S.H., dated July 3, 2018, the shareholders agreed to increase the authorized share capital of GOF from Rp40,000,000,000 to Rp106,000,000,000 and also increase the issued and fully paid share capital from Rp30,300,000,000 to Rp96,300,000,000, which have been issued and fully paid by Danfar and Finusolprima. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-0014334.AH.01.02 dated July 16, 2018.

Berdasarkan Akta Notaris Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., No. 13 tanggal 16 Desember 2019, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh GOF dari Rp96.300.000.000 menjadi Rp98.300.000.000, yang telah ditempatkan dan disetor penuh oleh Danfar dan Finusolprima. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0375743 tanggal 19 Desember 2019.

Based on Notarial Deed No. 13 of Tisha Sophy Pattinama, S.H., M.Kn., L.L.M., dated December 16, 2019, the shareholders agreed to increase the issued and fully paid share capital of GOF from Rp96,300,000,000 to Rp98,300,000,000, which have been issued and fully paid by Danfar and Finusolprima. The aforesaid change was acknowledged by the Ministry of Law and Human Rights of the Republic of Indonesia in its Decision Letter No. AHU-AH.01.03-0375743 dated December 19, 2019.









24




(d) Berdasarkan Akta Jual Beli Saham Christina Dwi Utami, S.H., M.Hum., M.Kn., No. 27 tanggal 3 September 2020, Perusahaan dan Danfar sepakat untuk menjual seluruh saham GOF yang dimiliki oleh Danfar kepada Perusahaan. Dengan perubahan tersebut, persentase kepemilikan Perusahaan dan Finusolprima di GOF menjadi masing-masing sebesar 90% dan 10%.

(d) Based on the Deed of Sale and Purchase of Shares No. 27 of Christina Dwi Utami, S.H., M.Hum., M.Kn., dated September 3, 2020, the Company and Danfar agreed to sell shares of GOF owned by Danfar to the Company. With the aforesaid change, the percentage of ownership of the Company and Finusolprima in GOF is 90% and 10%, respectively.

(e) Berdasarkan pernyataan keputusan para pemegang saham Danfar yang ditandatangani pada tanggal 20 Desember 2017 dan diaktakan dalam Akta Notaris Sri Buena Brahmana, S.H., M.Kn., No. 12 tanggal 15 Januari 2018, para pemegang saham sepakat untuk meningkatkan modal ditempatkan dan disetor penuh Danfar dari Rp20.000.000.000 menjadi Rp50.000.000.000, yang telah ditempatkan dan disetor penuh oleh Perusahaan dan Finusolprima. Perubahan tersebut telah dicatatkan pada Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dalam Surat Keputusan No. AHU-AH.01.03-0060989 tanggal 9 Februari 2018.

(e) Based on Danfar’s shareholders’ statement of decree which was signed on December 20, 2017 and covered by Notarial Deed No. 12 of Sri Buena Brahmana S.H., M.Kn., dated January 15, 2018, the shareholders agreed to increase the issued and fully paid share capital of Danfar from Rp20,000,000,000 to Rp50,000,000,00

PT Kalbe Farma Tbk. dan Entitas Anaknya/and its Subsidiaries · 2020. 10. 30. · PT Kalbe Farma...

Documents

Transcript of PT Kalbe Farma Tbk. dan Entitas Anaknya/and its Subsidiaries · 2020. 10. 30. · PT Kalbe Farma...